Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term diquafosol sodium for tear film homeostasis in children using orthokeratology with 0.01% atropine
ChiCTR2600131577Phase 4Completed
- Sponsor
- Nanjing Aier Eye Hospital
- Start
- Jan 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of diquafosol and atropine in dry eye syndrome (DED) (2 arms), sponsored by Nanjing Aier Eye Hospital. Primary endpoints: Lipid layer thickness at 3 months, Tear meniscus height at 3 months and 4 more. Started Jan 2024; status: completed.
02
Drugs
diquafosolatropine
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on ChiCTR2600131577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131577.